Micafungin Accord (Micafungin)

Micafungin works by inhibiting the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for producing β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. Disruption of cell‑wall synthesis leads to loss of integrity, osmotic instability and ultimately fungal cell death.

The dose of Micafungin Accord is determined by the prescribing clinician based on the specific infection being treated, patient weight, renal and hepatic function, and any relevant clinical guidelines. No fixed dosing regimen is provided here; the prescriber sets the appropriate regimen for each individual patient.

Safety data for Micafungin in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the uncertainties with the patient and consider alternative therapies when appropriate.

To order Micafungin Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if needed) and assists with import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to ergosterol. Echinocandins, including Micafungin, have a favorable safety profile and limited drug‑drug interactions, but are administered intravenously, unlike many oral azoles. Choice of therapy depends on infection type, patient condition and susceptibility patterns.

Micafungin Accord should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain to preserve stability and potency.

Micafungin is given by intravenous infusion. The vial is reconstituted with the appropriate diluent and administered over approximately one hour, as directed by the prescribing clinician. Infusion rates and dilution volumes are determined by the prescriber based on patient factors and clinical guidelines.

The most serious adverse reactions to monitor include hepatic failure, severe hypersensitivity reactions such as anaphylaxis, acute renal impairment, and severe hypotension. Prompt recognition and discontinuation of the drug are essential if any of these events occur.

Micafungin Accord should not be used in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised in patients with severe liver disease, and it is generally avoided in pregnancy and lactation unless the benefit clearly outweighs the risk.